Literature DB >> 34704302

Assessment of sleep disturbance in oral lichen planus and validation of PSQI: A case-control multicenter study from the SIPMO (Italian Society of Oral Pathology and Medicine).

Daniela Adamo1, Elena Calabria1, Noemi Coppola1, Lorenzo Lo Muzio2, Michele Giuliani2, Lorenzo Azzi3, Vittorio Maurino3, Giuseppe Colella4, Raffaele Rauso4, Lucio Montebugnoli5, Davide Bartolomeo Gissi5, Mario Gabriele6, Marco Nisi6, Andrea Sardella7, Giovanni Lodi7, Elena Maria Varoni7, Amerigo Giudice8, Alessandro Antonelli8, Marco Cabras9, Alessio Gambino9, Paolo Vescovi10, Alessandra Majorana11, Elena Bardellini11, Giuseppina Campisi12, Vera Panzarella12, Francesco Spadari13, Sonia Marino13, Monica Pentenero14, Samuele Sutera14, Matteo Biasotto15, Margherita Gobbo15,16, Luca Guarda Nardini16, Umberto Romeo17, Gianluca Tenore17, Rosario Serpico4, Alberta Lucchese4, Carlo Lajolo18, Cosimo Rupe18, Massimo Aria19, Agostino Gnasso19, Michele Davide Mignogna1.   

Abstract

BACKGROUND: The wellbeing of oral lichen planus patients (OLPs) may be strongly influenced by a poor quality of sleep (QoS) and psychological impairment. The aims were to analyze the prevalence of sleep disturbance, anxiety, and depression in OLPs and to validate the Pittsburgh Sleep Quality Index (PSQI) in OLPs.
METHODS: Three hundred keratotic OLPs (K-OLPs), 300 with predominant non-keratotic OLP (nK-OLPs), and 300 controls were recruited in 15 Italian universities. The PSQI, Epworth Sleepiness Scale (ESS), Hamilton Rating Scales for Depression and Anxiety (HAM-D and HAM-A), Numeric Rating Scale (NRS), and Total Pain Rating Index (T-PRI) were administered.
RESULTS: Oral lichen planus patients had statistically higher scores than the controls in the majority of the PSQI sub-items (p-values < 0.001**). Moreover, OLPs had higher scores in the HAM-D, HAM-A, NRS, and T-PRI (p-values < 0.001**). No differences in the PSQI sub-items' scores were found between the K-OLPs and nK-OLPs, although nK-OLPs suffered from higher levels of anxiety, depression, and pain (p-values: HAM-A, 0.007**, HAM-D, 0.009**, NRS, <0.001**, T-PRI, <0.001**). The female gender, anxiety, depression (p-value: 0.007**, 0.001**, 0.020*) and the intensity of pain, anxiety, and depression (p-value: 0.006**, <0.001**, 0.014*) were independent predictors of poor sleep (PSQI > 5) in K-OLPs and nK-OLPs, respectively. The PSQI's validation demonstrated good internal consistency and reliability of both the total and subscale of the PSQI.
CONCLUSIONS: The OLPs reported an overall impaired QoS, which seemed to be an independent parameter according to the regression analysis. Hence, clinicians should assess QoS in OLPs and treat sleep disturbances in order to improve OLPs management.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  anxiety; insomnia; mood disturbance; oral lichen planus; sleep disturbance

Mesh:

Year:  2021        PMID: 34704302     DOI: 10.1111/jop.13255

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  1 in total

1.  Where do you live? North versus Central-South differences in relation to Italian patients with oral lichen planus: a cross-sectional study from the SIPMO (Italian Society of Oral Pathology and Medicine).

Authors:  Daniela Adamo; Elena Calabria; Federica Canfora; Noemi Coppola; Lorenzo Lo Muzio; Francesca Spirito; Michele Giuliani; Lorenzo Azzi; Vittorio Maurino; Giuseppe Colella; Chiara Colella; Lucio Montebugnoli; Davide Bartolomeo Gissi; Mario Gabriele; Marco Nisi; Andrea Sardella; Giovanni Lodi; Elena Maria Varoni; Amerigo Giudice; Alessandro Antonelli; Paolo Giacomo Arduino; Alessio Gambino; Paolo Vescovi; Alessandra Majorana; Elena Bardellini; Giuseppina Campisi; Vera Panzarella; Francesco Spadari; Umberto Garagiola; Monica Pentenero; Samuele Sutera; Matteo Biasotto; Giulia Ottaviani; Margherita Gobbo; Luca Guarda Nardini; Umberto Romeo; Gianluca Tenore; Rosario Serpico; Alberta Lucchese; Carlo Lajolo; Cosimo Rupe; Massimo Aria; Luca D'Aniello; Michele Davide Mignogna
Journal:  BMC Oral Health       Date:  2022-05-18       Impact factor: 3.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.